Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs

被引:2
|
作者
Mor Rangel, Marcelo Monte [1 ]
Menescal Linhares, Lais Calazans [2 ]
de Oliveira, Krishna Duro [3 ]
Hisayasu Suzuki, Daniela Ota [4 ]
Maglietti, Felipe Horacio [5 ]
de Nardi, Andrigo Barboza [2 ]
机构
[1] VetCanc Vet Oncol, Sao Paulo, SP, Brazil
[2] Sao Paulo State Univ UNESP Julio de Mesquita Filh, Sch Agr & Vet Sci, Jaboticabal, SP, Brazil
[3] VCLab Pathol, Sao Paulo, SP, Brazil
[4] Fed Univ Santa Catarina UFSC, Inst Biomed Engn, Florianopolis, SC, Brazil
[5] Fdn Barcelo CONICET, Inst Univ Ciencias Salud, Buenos Aires, DF, Argentina
关键词
TRANSITIONAL-CELL CARCINOMA; CORN-ROOTWORM COLEOPTERA; URINARY-BLADDER; CANINE BLADDER; UROTHELIAL CARCINOMA; RADIATION-THERAPY; OVIPOSITION-SITE; ELECTRIC PULSES; PARTIAL CYSTECTOMY; CLIMATE-CHANGE;
D O I
10.1038/s41598-023-45433-4
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Local treatment of canine urothelial carcinoma (UC) of the bladder is a challenge. More than 90% of the cases invade the muscular layer, more than 50% develop on bladder sites with a difficult surgical approach and often requiring radical surgical procedures. This study aims to evaluate the safety and feasibility of electrochemotherapy (ECT) with intravenous bleomycin (BLM) as a local therapy for bladder UC. This prospective study included 21 dogs with spontaneous bladder UC. Regional/distant metastases and neoplastic infiltration of the serosa was considered the main exclusion criteria. We had no deaths during ECT or in the immediate postoperative period, and no suture dehiscence. Most dogs (19/21) developed mild adverse effects, whereas two dogs developed ureteral stenosis. Complete response (CR) was achieved in 62% of the cases (13/21), while partial response (PR) was achieved in 24% (5/21). The median survival and disease-free survival times were 284 and 270 days, respectively. Overall survival was significantly better in the dogs who achieved a CR. In conclusion, ECT was well-tolerated in dogs with UC, demonstrating its safety and feasibility. These data pave the way for new studies aimed at evaluating the effectiveness of ECT in canine bladder UC as a translational model for human disease.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Local treatment with electrochemotherapy of superficial angiosarcomas: Efficacy and safety results from a multi-institutional retrospective study
    Guida, M.
    Campana, L.
    Curatolo, P.
    Strippoli, S.
    Bonadies, A.
    Grilz, G.
    Cabula, C.
    Rotunno, R.
    Bucher, S.
    Solari, N.
    Santoriello, A.
    Valpione, S.
    Rossi, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [42] Bladder cancer treatment in the medicare population: Predictors of intravenous chemotherapy and cystectomy
    Porter, MP
    Kerrigan, MC
    Ramsey, SD
    JOURNAL OF UROLOGY, 2006, 175 (04): : 12 - 12
  • [43] Intravenous and Intramuscular Allopregnanolone for Early Treatment of Status Epilepticus: Pharmacokinetics, Pharmacodynamics, and Safety in Dogs
    Vuu, Irene
    Patterson, Edward E.
    Wu, Chun-Yi
    Zolkowska, Dorota
    Leppik, Ilo E.
    Rogawski, Michael A.
    Worrell, Gregory A.
    Kremen, Vaclav
    Cloyd, James C.
    Coles, Lisa D.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2022, 380 (02): : 104 - 113
  • [44] Evaluation and Treatment of Overactive Bladder after History of Cancer Treatment
    Jellison F.C.
    Current Bladder Dysfunction Reports, 2015, 10 (1) : 31 - 38
  • [45] Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcome
    Wiken, T.
    Hoivik, M. L.
    Buer, L.
    Bolstad, N.
    Moum, B. A.
    Medhus, A. W.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I378 - I379
  • [46] Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcome
    Wiken, T.
    Hoivik, M. L.
    Buer, L.
    Bolstad, N.
    Moum, B. A.
    Medhus, A. W.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I378 - I379
  • [47] Efficacy and Safety of Resveratrol in the Treatment of Bladder Cancer Derived Organoids
    Liu, Guang-Yao
    Xiao, Kang-Hua
    Li, Hong
    Chen, Xiang
    Ye, Hai-Shan
    Liu, Lin-Jie
    Li, Ting-Ting
    Li, Sheng
    Lu, Jun-Lin
    Chen, Xu
    Liu, Jia
    ADVANCED THERAPEUTICS, 2024, 7 (06)
  • [48] Evaluation of efficacy and safety of intralesional bleomycin in the treatment of common warts: Results of a pilot study
    Mehta, Karan Inder Singh
    Mahajan, Vikram K.
    Chauhan, Pushpinder Singh
    Chauhan, Shailja
    Sharma, Vikas
    Rawat, Ritu
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2019, 85 (04): : 397 - 404
  • [49] ELECTROCHEMOTHERAPY (ECT) WITH BLEOMYCIN AS A PALLIATIVE TREATMENT OF REGIONAL RELAPSE IN HEAD AND NECK CANCER (H&NC) PATIENTS (PTS). A PILOT STUDY
    Grau, J. J.
    Caballero, M.
    Vilalta, A.
    Victoria, I.
    Reig, O.
    Gascon, P.
    Carrera, C.
    Malvehy, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 343 - 343
  • [50] Safety, feasibility, and quality of thulium laser en-bloc resection for treatment of non-muscle invasive bladder cancer
    Assem, Ahmed
    Kassem, Ayman
    Sherif, Mohamed
    Lotfi, Amr
    Abdelwahed, Mohamed
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2023, 55 (12) : 3103 - 3109